Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Divestments (2022 - 2023)

Historic Divestments for Marker Therapeutics (MRKR) over the last 2 years, with Q2 2023 value amounting to $18.8 million.

  • Marker Therapeutics' Divestments changed N/A to $18.8 million in Q2 2023 from the same period last year, while for Dec 2023 it was $18.7 million, marking a year-over-year change of. This contributed to the annual value of $18.7 million for FY2023, which is 47742.38% up from last year.
  • According to the latest figures from Q2 2023, Marker Therapeutics' Divestments is $18.8 million.
  • Marker Therapeutics' Divestments' 5-year high stood at $18.8 million during Q2 2023, with a 5-year trough of -$127342.0 in Q4 2022.